Agape ATP Corp: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 11:07 ET.
Management's discussion and analysis
As filed, 43,971 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 31, 2021, for the year ended December 31, 2020 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.
The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.
Company Overview
Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.
Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.
Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.
On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.
Agape Superior Living Sdn. Bhd. (“ASL”) is a limited company incorporated on August 8, 2003, under the laws of Malaysia.
On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On September 15, 2020, WATP entered into a business collaboration agreement with ASL to carry out certain wellness programs.
The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.
Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.
In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.
The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.
The Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.
The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.
The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.
The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.
Results of Operation
For the three months ended September 30, 2021 and 2020
Revenue
We generated revenue of $201,284 for the three months ended September 30, 2021 as compared to $1,413,063 for the three months ended September 30, 2020, representing a significant decrease of $1,211,779 or approximately 85.8%. The significant decrease was mainly due to the COVID-19 situation in Malaysia which has turned more severe in the quarter ended September 30, 2021 as compared to the corresponding period in 2020. As such, it has adversely affected us. From CMCO, the entire country was again placed under full lockdown effective May 12, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since October 3, 2021. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated. The lockdowns disrupted much of our operational activities, which led to the significant decrease in revenue for the three months ended September 30, 2021 as compared to the same period in 2020. Economically, the prolonged pandemic will adversely affect the purchasing power of consumers in Malaysia.
Cost of Revenue
Cost of revenue for the three months ended September 30, 2021 amounted to $36,663 as compared to $186,891 for the three months ended September 30, 2020, representing a significant decrease of $150,228 or approximately 80.4%. The cost of revenue comprised freight-in, cost of goods purchased, and packing materials. The significant decrease in cost of revenue for the three months ended September 30, 2021 as compared to the same period in 2020, was in line with the significant decrease in our revenues. As explained in the above, much of our operational activities was disrupted as a result of the resurgence of COVID-19 infection and movement control orders imposed in Malaysia as explained above.
Gross Profit
Gross profit for the three months ended September 30, 2021 amounted to $164,621 as compared to $1,226,172 for the three months ended September 30, 2020. Gross margin for the three months ended September 30, 2021 was approximately 81.8% as compared to approximately 86.8% for the three months ended September 30, 2020. As explained in the above, the decrease in gross profit was attributed to the significant decrease in revenue due to the disruption of our operational activities. In its effort to boost sales, the Company also lowered its product gross margin during the quarter. The Company did not achieve the results that we initially forecasted due to the severity of the COVID-19 situation in the Malaysia as explained above.
Operating Expenses
Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.
Selling expenses
Selling expenses for the three months ended September 30, 2021 amounted to $82,854 as compared to $159,292 for the three months ended September 30, 2020, a decrease of $76,438 or approximately 48.0%. The decrease was mainly due to fewer promotional activities performed in the face of the severity of the COVID-19 pandemic.
Commission expenses
Commission expenses were $76,817 and $300,957 for the three months ended September 30, 2021 and 2020, respectively, representing a significant decrease of $224,140 or approximately 74.5%. The significant decrease in commission expenses was in line with the significant decrease in revenue.
General and administrative expenses
General and administrative expenses for the three months ended September 30, 2021 amounted to $369,946, as compared to $355,274 for the three months ended September 30, 2020, representing an increase of $14,672 or approximately 4.1%. The increase was mainly due to the increase of professional fees for the preparation of the Company’s U.S. tax return.
Other (Expenses) Income
For the three months ended September 30, 2021, we recorded an amount of $220,812 as other expenses, net as compared to $62,329 other income, net for the three months ended September 30, 2020, representing a significant decrease of $283,141 or approximately 454.3%. The net other expenses of $220,812 incurred during the three months ended September 30, 2021 comprised of other expense of $11,643 and unrealized holding loss on marketable securities of $209,169. The net other income of $62,329 incurred during the three months ended September 30, 2020 comprised other income of $86,748 and unrealized holding loss on marketable securities of $24,419.
Benefit of (Provision for) Income Taxes
We recognized benefit of income taxes $14,543 and provision for income taxes $57,941 for the three months ended September 30, 2021 and 2020, respectively. During the three months ended September 30, 2021, we mainly recognized our ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits. On the other hand, during the three months ended September 30, 2020, we generated taxable income in ASL that was subjected to a unified 24% income tax rate.
Net (Loss) Income
We incurred a net loss of $571,265 for the three months ended September 30, 2021, from a net income of $415,037 for the three months ended September 30, 2020, a decrease of $986,302, predominately due to reasons as discussed above.
For the nine months ended September 30, 2021 and 2020
Revenue
We generated revenue of $806,850 for the nine months ended September 30, 2021 as compared to $2,936,925 for the nine months ended September 30, 2020, representing a significant decrease of $2,130,075 or approximately 72.5%. It is to be noted that as between the two nine-months period, ASL contributed revenue throughout the entire nine months ended September 30, 2021, whereas ASL’s revenue contribution to us only began from April 1, 2020 to September 30, 2020, after the acquisition on May 8, 2020. For the period from January 1, 2020 to March 31, 2020, we were only making sales to our related party on wholesale basis when ASL placed the purchase orders. Despite a full nine months revenue contribution from ASL, which brought us a large group of customers in an established network marketing sales channel that has been in established in Malaysia for the past 15 years, the $2,130,075 reduction in revenue for the nine months ended September 30, 2021, was due to the COVID-19 situation in Malaysia which has turned more severe as explained above. From CMCO, the entire country was again placed under full lockdown effective May 12, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since October 3, 2021. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated. The lockdowns disrupted much of our operational activities, which led to the significant decrease in revenue for the nine months ended September 30, 2021 as compared to the same period in 2020. Economically, the prolonged pandemic will adversely affect the purchasing power of consumers in Malaysia.
Cost of Revenue
Cost of revenue for the nine months ended September 30, 2021 amounted to $149,877 as compared to $658,445 for the nine months ended September 30, 2020, representing a significant decrease of $508,568 or approximately 77.2%.
The cost of revenue comprised freight-in, cost of goods purchased, and packing materials. The significant decrease in cost of revenue for the nine months ended September 30, 2021 as compared to the same period in 2020, was in line with the significant decrease in our revenues. As explained in the above, much of our operational activities was disrupted as a result of the resurgence of COVID-19 infection and movement control orders imposed in Malaysia as explained above.
Gross Profit
Gross profit for the nine months ended September 30, 2021 amounted to $656,973 as compared to $2,278,480 for the nine months ended September 30, 2020. Gross margin for the nine months ended September 30, 2021 was approximately 81.4% as compared to approximately 77.6% for the nine months September 30, 2020. Gross margin for the two nine months period is less comparable due to (i) change in our business activities from wholesale business to retail activities effective April 1, 2020. Typically, selling our products directly to the customers in the network channel generates higher gross margins as compared to gross margins from our sales to our related party wholesales customers; and (ii) the adverse economic impact brought about by the COVID-19 pandemic. We had to adhere to the MCO which disrupted our operations for the nine months ended September 30, 2021.
Operating Expenses
Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.
Selling expenses
Selling expenses for nine months ended September 30, 2021 amounted to $299,806 as compared to $268,648 for the nine months ended September 30, 2020, representing an increase of $31,158 or approximately 11.6%. The increase was mainly due to selling expenses incurred for the nine months ended September 30, 2021 encompassed selling expenses incurred by ASL for the entire nine months period, whereas selling expenses for the corresponding period last year in connection to ASL’s retail activities only began form April 1, 2020 to September 30, 2020 after its acquisition on May 8, 2020. The Company incurred higher salaries and benefits expenses for the current nine months period, as it represented a full nine months from January 1, 2021 to September 30, 2021, but lower other selling expenses as compared to the corresponding period last year where we incurred selling expenses from ASL from April 1, 2020 to September 30, 2020.
Commission expenses
Commission expenses were $258,030 and $683,455 for the nine months ended September 30, 2021 and 2020, respectively, representing a significant decrease of $425,425 or approximately 62.2%. The significant decrease in commission expenses was in line with the decrease in revenue as our sales activities was disrupted due to the many lockdowns imposed by the government of Malaysia as a direct result of the resurgence of COVID-19 infections in Malaysia as explained above.
General and administrative expenses
General and administrative (“G&A”) expenses for nine months ended September 30, 2021, amounted to $1,094,042 as compared to $1,029,052 for the nine months ended September 30, 2020, an increase of $64,990 or approximately 6.3%. G&A expenses for nine months ended September 30, 2021 encompassed G&A expenses incurred by ASL for the entire nine months period, whereas G&A expenses for the corresponding period last year in connection to ASL’s retail activities only began from April 1, 2020 to September 30, 2020, after its acquisition on May 8, 2020.
G&A expenses increased marginally, by approximately 6.3%, as most G&A expenses incurred for the nine months ended September 30, 2020 were directly related to the acquisition of ASL, which exercise was completed in April in 2020. The expenses were therefore not expected to recur.
G&A expenses for the nine months ended September 30, 2021 comprised of professional fees of $303,880 for legal counsel, auditor, and financial reporting consultant in the U.S. and Hong Kong, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and continue to stay compliant, salary and employee benefit expenses of $464,494, rental expenses of $135,865, depreciation expenses of $56,919 and other general and administrative expenses of $132,884.
G&A expenses for the nine months ended September 30, 2020 comprised of professional fees of $486,870 for legal counsel, auditor, and financial reporting consultant in the U.S. and Hong Kong, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and continue to stay compliant, salary and employee benefit expenses of $275,068, rental expenses of $111,465, travelling expenses for our CEO for potential business developments of $34,000, depreciation expenses of $36,524 and other general and administrative expenses of $85,125.
Provision for doubtful accounts
Provision for doubtful accounts were $121,686 and $0 for the nine months ended September 30, 2021 and 2020, respectively, a significant increase of $121,686 or 100.0%. The provision for doubtful accounts was in respect of prepayments to a supplier. As the prepayments remain outstanding for over a year, the likelihood of recovering the prepayments is remote.
Other Income (Expenses)
For the nine months ended September 30, 2021, we recorded an amount of $435,089 as other expenses, net, as compared to $165,210 other income, net, for the nine months ended September 30, 2020, representing a significant decrease of $600,299 or approximately 363.4%. The net other expenses of $435,089 incurred during the nine months ended September 30, 2021 comprised of other expenses of $60,189 and unrealized holding loss on marketable securities of $374,900. The net other income of $165,210 recognized during the nine months ended September 30, 2020 comprised other income of $62,963 and unrealized holding gain on marketable securities of $102,247.
Benefit of (Provision for) Income Taxes
We recorded benefit of income taxes $4,452 and provision for income taxes $192,008 for the nine months ended September 30, 2021 and 2020, respectively. During the nine months ended September 30, 2021, we mainly recognized our ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits. On the other hand, during the nine months ended September 30, 2020, we generated taxable income in ASL that was subjected to a unified 24% income tax rate.
Net Income (Loss)
We had net loss of $1,547,140 for the nine months ended September 30, 2021, compared with net income of $270,527 for the nine months ended September 30, 2020, , mainly due to reasons as discussed above.
Liquidity and Capital Resources
On March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. To help counter the transmission of COVID-19, the government of Malaysia initiated movement control orders (“MCO”), the first effective March 18, 2020. The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. The first MCO was extended three times, each for a two-weeks period, until May 12, 2020. On May 13, 2020, the MCO was eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia. The CMCO was further relaxed, and on June 8, 2020, Malaysia moved into the Recovery Movement Control Order (“RMCO”). Due to a resurgence of COVID-19, CMCO was reimposed in the state of Sabah, Selangor, Kuala Lumpur and Putrajaya effective October 14, 2020. On November 7, 2020, the CMCO was extended to a wider geographical area to include another six states in the country. Effectively, ten of thirteen states in Malaysia were placed under CMCO with the exceptions of Perlis, Pahang and Kelantan. On January 1, 2021, the Government of Malaysia extended the Recovery Movement Control Order (“RMCO”) through March 31, 2021. On January 12, 2021, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country.
On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country is administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population. The government is preparing to shift into an endemic COVID-19 phase where it will not impose wide lockdowns even if cases rise. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated.
Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:
- temporary closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially resulting in which the demand for our products may be adversely affected;
- we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results; and
- any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.
Although some of the countries from which our products are sourced are experiencing lockdowns, industries involve in the provision of food especially health products and pharmaceuticals are normally exempted. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.
We currently operate primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. When the pandemic has subsided or is over and restrictions on travelling between nations are uplifted, we will set up offices in the countries in which we operate to better service our customers.
Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the remaining period of 2021 and in 2022.
As of September 30, 2021, we had working capital of $3,307,503 consisting of cash in bank of $847,773 and time deposits of $2,032,119 as compared to working capital of $4,645,729 consisting of cash in bank of $1,112,147 and time deposits of $2,391,182 as of December 31, 2020. In assessing our liquidity, we monitor and analyze our cash on-hand and our operating expenditure commitments. Our liquidity needs are to meet our working capital requirements and operating expenses obligations. We believe we will have sufficient resource to fund our working capital needs for the next 12 months from the date of issuance of this Form 10-Q.
The following summarizes the key components of our cash flows for the nine months ended September 30, 2021 and 2020:
| For the Nine Months Ended September 30, 2021 | September 30, 2020 | |
|---|---|---|
| Net cash used in operating activities | $(541,440) | $(743,670) |
| Net cash (used in) provided by investing activities | (3,970) | 1,276,114 |
| Net cash (used in) provided by financing activities | (23,280) | 21,104 |
| Effect of exchange rate on cash and cash equivalents | (68,233) | 45,585 |
| Net change in cash and cash equivalents | $(636,923) | $599,133 |
Operating activities
Net cash used in operating activities for the nine months ended September 30, 2021 was $541,440 and were mainly comprised of the net loss of $1,547,140, deferred tax benefit of $131,634, decrease in prepayments and deposits of $4,309, decrease in customer deposits of $44,044, payment of operating lease liabilities of $111,460 and decrease in other payables and accrued liabilities of $123,082. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $58,401, amortization of operating right-of-use assets of $112,678, unrealized holding loss on marketable securities of $374,900, inventories write-down of $36,636, provision for doubtful accounts of $121,598, decrease in accounts receivables of $168,019, decrease in inventories of $90,580, refund in prepaid taxes of 431,224 and decrease in income tax payables of $26,193.
Net cash used in operating activities for the nine months ended September 30, 2020 was $743,670 and were predominately comprised of the non-cash income on unrealized holding gain on marketable securities of $102,247, increase in accounts receivables of $271,876, increase in amount due from a related party of $1,443, increase in prepaid taxes of $123,507, decrease in customer deposits of $1,268,487, payment of operating lease liabilities of $69,021 and decrease in accounts payable of $2,804. The net cash used in operating activities was mainly offset by net income of $270,527, non-cash depreciation and amortization expense of $37,517, amortization of operating right-of-use assets of $70,047, deferred tax provision of $171,586, decrease in inventories of $132,939, decrease in prepayments and deposits, including related party of $245,496, and increase in other payables and accrued liabilities of $167,603.
Investing activities
Net cash used in investing activities for the nine months ended September 30, 2021 was $3,970, which was in respect of purchase of equipment.
Net cash provided by investing activities for the nine months ended September 30, 2020 was $1,276,114, which were in respect of cash and cash equivalents acquired through acquisition of ASL of $1,210,818 and partial proceeds collected from the sale of our non-marketable securities of $70,173, offset by purchase of equipment and intangible assets of $4,877.
Financing activities
Net cash used in financing activities for the nine months ended September 30, 2021 was $23,280 which were mainly comprised of payment of deferred offering cost of $15,210 and advances to related parties of $8,070.
Net cash provided by financing activities for the nine months ended September 30, 2020 was $21,104 which were mainly comprised of repayments from related parties of $224,342 offset by payment of deferred offering cost of $203,238.
Credit Facilities
We do not have any credit facilities or other access to bank credit.
Off-Balance Sheet Arrangements
As of September 30, 2021, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.
Critical Accounting Polices
Use of estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.
Revenue recognition
The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.
The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.
The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.
The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.
Sales of Health and Wellness products
- Performance obligations satisfied at a point in time
The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.
The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.
Sales of Health and Wellness services
- Performance obligations satisfied at a point in time
The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person. The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp.
Fair value of financial instruments
The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.
The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:
- Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
- Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.
Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.
Recent accounting pronouncements
The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:
In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.
In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.
In October 2020, the FASB issued ASU 2020-08, “Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs”. The amendments in this Update represent changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021. Early application is not permitted. All entities should apply the amendments in this Update on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.
In October 2020, the FASB issued ASU 2020-10, “Codification Improvements”. The amendments in this Update represent changes to clarify the Codification or correct unintended application of guidance that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 for public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.
Market risk
As filed, 1,341 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Foreign exchange risk. Substantially most of our revenues are denominated in the U.S. dollar while most of our expenses are denominated in Malaysian Ringgit and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.
Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.
Controls and procedures
As filed, 8,494 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
Disclosures Control and Procedures
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:
- Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
- Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
As of September 30, 2021, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on such evaluation, the Company’s management concluded that, during the period covered by this Report, internal controls and procedures over financial reporting were not effective. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.
Identified Material Weakness
A material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.
Management identified the following material weakness during its assessment of internal controls over financial reporting as of September 30, 2021: (i) we did not have sufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii) we lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures; lack of adequate policies and procedures in internal audit function to ensure that our policies and procedures have been carried out as planned; (iii) we do not have adequate segregation of duties and effective risk assessment. Lack of segregation of duties and effective risk assessment may cause us to face the likelihood of fraud or theft, due to poor oversight, governance and review to detect errors; (iv) we lack of proper procedures developed for system change management policies. Critical change management control processes and procedures, such as change request and approval, periodic status reporting, user testing and acceptance, post-implementation review, etc., were either not performed or formally documented; (v) we lack of the following internal control procedures in relation of System and Data Security Access: (a) authorization of new operating system-level user accounts created was not formally documented, (b) periodic review and recertification of application, operating system, and database users and the user access rights was not performed, (c) procedures for periodic review and analysis of application, operating system, and database-level audit logs were not documented or performed, manually or through the use of software tools, (d) mandatory password settings, such as minimum length, complexity, reset frequency, failed log-in attempts, password history, etc., were not deployed; and (vi) we lack of qualified person to be able to provide the tax provision for the U.S. income taxes in connection with the Subpart F and GILTI taxable income.
Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.
As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of September 30, 2021 based on criteria established in Internal Control—Integrated Framework issued by COSO.
Management’s Remediation Initiatives
In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.
We have initiated and plan to initiate the following series of measures to further strengthen the Company’s internal controls going forward:
1. On January 12, 2021, the Company has appointed a Chief Finance Officer with appropriate levels of accounting knowledge and experience to monitor the recording of transactions, address complex U.S. GAAP accounting issues and to review financial statements and related disclosures under U.S. GAAP.
2. We intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.
3. We intend to engage an external consulting firm to supplement our efforts to the implementation of the 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework for internal controls.
4. Once we hire additional employees, we intend to initiate a comprehensive training program and development plan to provide ongoing company-wide trainings regarding internal control and requirements of U.S. GAAP financial statements and related disclosures, with particular emphasis on our accounting staff.
5. We are seeking a U.S. tax professional to assist in the preparation of the Subpart F and GILTI tax provisions
We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2021.
Changes in Internal Control over Financial Reporting:
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $201.3k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $806.9k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-07-01 to 2021-09-30 | $36.7k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2021-01-01 to 2021-09-30 | $149.9k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-07-01 to 2021-09-30 | $164.6k | us-gaap:GrossProfit |
| Gross profit | 9 months2021-01-01 to 2021-09-30 | $657.0k | us-gaap:GrossProfit |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$365.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-07-01 to 2021-09-30 | −$14.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | −$4.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$571.3k | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$1.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$541.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-09-30 | $2.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $4.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $5.3m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $866.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $983.9k | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-09-30 | $4.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-21-028076. Last ingested by Listed: Nov 6, 2026, 16:53 ET. Listed shows no prices and gives no investment advice.